Salix Pharmaceuticals announced this week that the Food and Drug Administration has accepted its new drug application for Budesonide, a rectal foam used to treat patients with ulcerative colitis.
The FDA expects to issue a ruling on the application on Sept. 15.
Raleigh-based Salix sells drugs to treat gastrointestinal ailments. Earlier this year, Salix completed its $2.6 billion acquisition of the specialty drug company Santarus, which focuses on similar areas of treatment.
Staff writer David Bracken
Sign Up and Save
Get six months of free digital access to The News & Observer